eligibility_summary
Inclusion: adults (≥18) with histo/cytology-confirmed oral SCC scheduled for surgical resection at UMCG, consented. Exclusion: inability to consent, uncontrolled comorbidities, investigational drug <30 days, recent (≤6 mo) MI/CVA/unstable angina/CHF, significant liver disease, uncontrolled hypertension, cetuximab/mAb allergy, pregnant/lactating (neg test + contraception ×6 mo), QT prolongation, on Class Ia/III antiarrhythmics, life expectancy <12 weeks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Cetuximab (75 mg, chimeric IgG1 anti‑EGFR monoclonal antibody) plus cetuximab‑IRDye800CW (15 mg, near‑infrared fluorescent antibody–dye conjugate) administered to enable fluorescence‑guided intraoperative detection of tumor‑positive margins, combined with fresh‑frozen sectioning guided by the fluorescence signal. Mechanisms: Cetuximab binds EGFR (ErbB1) on tumor cells, the IRDye800CW label generates a tumor‑specific NIR signal to localize residual disease. Cetuximab also inhibits EGFR signaling (MAPK/PI3K) and can mediate ADCC, though here it serves primarily as an imaging targeter. Targets: EGFR‑overexpressing head and neck squamous carcinoma cells at surgical margins, EGFR/ErbB pathway.